Mengli Huang

1.5k total citations · 1 hit paper
67 papers, 879 citations indexed

About

Mengli Huang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Mengli Huang has authored 67 papers receiving a total of 879 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 30 papers in Pulmonary and Respiratory Medicine and 18 papers in Cancer Research. Recurrent topics in Mengli Huang's work include Cancer Immunotherapy and Biomarkers (20 papers), Cancer Genomics and Diagnostics (13 papers) and Lung Cancer Treatments and Mutations (10 papers). Mengli Huang is often cited by papers focused on Cancer Immunotherapy and Biomarkers (20 papers), Cancer Genomics and Diagnostics (13 papers) and Lung Cancer Treatments and Mutations (10 papers). Mengli Huang collaborates with scholars based in China, United States and Poland. Mengli Huang's co-authors include Yuezong Bai, Shangli Cai, Jing Zhao, Wenzhuan Xie, Yuzi Zhang, Xiaochen Zhao, Shiqing Chen, Guoqiang Wang, Zhengyi Zhao and Longgang Cui and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Mengli Huang

65 papers receiving 872 citations

Hit Papers

Use of Immunotherapy With Programmed Cell Death 1 vs Prog... 2019 2026 2021 2023 2019 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
    2019 249 citations Xiaochen Zhao, Shiqing Chen et al. profile →

Peers

Mengli Huang
Tongxin Liu China
Han Hsi Wong United Kingdom
Benjamin Ruf United States
Haijing Deng China
Yinan Shen China
Rebecca Kesselring Germany
E. Mezza Italy
Z. Mark United States
Eun Shin South Korea
Md. Hafiz Uddin United States
Tongxin Liu China
Mengli Huang
Citations per year, relative to Mengli Huang Mengli Huang (= 1×) peers Tongxin Liu

Countries citing papers authored by Mengli Huang

Since Specialization
Citations

This map shows the geographic impact of Mengli Huang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mengli Huang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mengli Huang more than expected).

Fields of papers citing papers by Mengli Huang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mengli Huang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mengli Huang. The network helps show where Mengli Huang may publish in the future.

Co-authorship network of co-authors of Mengli Huang

This figure shows the co-authorship network connecting the top 25 collaborators of Mengli Huang. A scholar is included among the top collaborators of Mengli Huang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mengli Huang. Mengli Huang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Guihua, Junwei Cao, Mengli Huang, & Meng Shang. (2025). Investigating the impact of user perception and gamification elements on repurchase decisions in game live broadcasting. Frontiers in Psychology. 16. 1492832–1492832. 1 indexed citations
2.
3.
4.
Guo, Feilong, Guoli Li, Long Ma, et al.. (2023). Efficacy of intra-arterial chemotherapy with sequential anti-PD-1 antibody in unresectable gastric cancer: A retrospective real-world study. Frontiers in Oncology. 12. 1015962–1015962. 8 indexed citations
5.
Yan, Kai, Ding Zhang, Yanan Chen, et al.. (2023). Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma. Frontiers in Immunology. 14. 1116057–1116057. 3 indexed citations
6.
Xu, Tongpeng, Wenjie Wang, Junling Zhang, et al.. (2023). Anti-PD-1 plus anti-angiogenesis combined with chemotherapy in patients with HER2-negative advanced or metastatic gastric cancer: a multi-institutional retrospective study. Journal of Gastrointestinal Oncology. 14(1). 175–186. 3 indexed citations
7.
Huang, Jiayuan, Jie Ni, Meng Song, et al.. (2023). Transformation of ALK-positive NSCLC to SCLC after alectinib resistance and response to combined atezolizumab: a case report. Translational Lung Cancer Research. 12(3). 637–646. 10 indexed citations
8.
Chen, Tianxiang, Jia Huang, Shengping Shen, et al.. (2023). Neoadjuvant Chemoimmunotherapy Increases Tumor Immune Lymphocytes Infiltration in Resectable Non-small Cell Lung Cancer. Annals of Surgical Oncology. 30(12). 7549–7560. 7 indexed citations
9.
Su, Xiaodong, Guangyu Luo, Zhiqiang Wang, et al.. (2023). Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial. Journal of Translational Medicine. 21(1). 411–411. 17 indexed citations
10.
Lv, Meng, Xuanyu He, Yating Zheng, et al.. (2022). Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma. Frontiers in Immunology. 13. 871756–871756. 6 indexed citations
11.
Jiang, Shiyu, Xianghua Wu, Wangjun Yan, et al.. (2022). Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study. Clinical Cancer Research. 28(24). 5280–5289. 20 indexed citations
12.
13.
Ye, Ting, Jieying Zhang, Xin-Yi Liu, et al.. (2022). The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma. Frontiers in Immunology. 12. 785526–785526. 7 indexed citations
14.
Huang, Jun, Wan He, Yandong Zhao, et al.. (2022). PD-1 blockade boosted chemo-target therapy in cT4NxM0 pMMR/MSS colorectal cancer.. Journal of Clinical Oncology. 40(16_suppl). e15606–e15606. 2 indexed citations
15.
Wang, Zhihong, Tianmei Zeng, Ding Zhang, et al.. (2021). PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature. Frontiers in Immunology. 12. 799822–799822. 6 indexed citations
16.
17.
Yu, Yunfang, Lintong Yao, Bin Xu, et al.. (2021). KEAP1/NFE2L2 Mutations of Liquid Biopsy as Prognostic Biomarkers in Patients With Advanced Non-Small Cell Lung Cancer: Results From Two Multicenter, Randomized Clinical Trials. Frontiers in Oncology. 11. 659200–659200. 17 indexed citations
18.
19.
Zhang, Rusi, Xuewen Zhang, Fang Wang, et al.. (2020). Development and validation of a preoperative noninvasive predictive model based on circular tumor DNA for lymph node metastasis in resectable non-small cell lung cancer. Translational Lung Cancer Research. 9(3). 722–730. 11 indexed citations
20.
Zhou, Taicheng, Zhihua Cai, Ning Ma, et al.. (2020). A Novel Ten-Gene Signature Predicting Prognosis in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology. 8. 629–629. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tongxin Liu Breakdown of academic impact, for papers by Han Hsi Wong Breakdown of academic impact, for papers by Benjamin Ruf Breakdown of academic impact, for papers by Haijing Deng Breakdown of academic impact, for papers by Yinan Shen Breakdown of academic impact, for papers by Rebecca Kesselring Breakdown of academic impact, for papers by E. Mezza Breakdown of academic impact, for papers by Z. Mark Breakdown of academic impact, for papers by Eun Shin Breakdown of academic impact, for papers by Md. Hafiz Uddin
Rankless by CCL
2026